Becton Dickinson & Co. closed 30.77% below its 52-week high of $251.99, which the company achieved on February 3rd.

BDX has dropped 25% since May 2024 vs. S&P 500’s 6% and MedTech’ Becton Dickinson's organic growth outlook cut to ~3–4%, down from ~5–6% two years ago. Ready to turn the market’s ...

Becton, Dickinson and Company has struggled over the past decade, with a 10-year CAGR of only 5.1%. Read what keeps me on the sidelines of BDX stock.

U.S. medical device maker Becton Dickinson is in talks with Thermo Fisher and Danaher for a potential sale of its life sciences unit, the Financial Times reported on Tuesday.

Medical devices maker Becton Dickinson has kicked off talks to divest its $21bn life sciences unit, engaging rivals including Thermo Fisher Scientific and Danaher, said people familiar with the ...

For its fiscal 2025 first quarter, which ended Dec. 31, Becton Dickinson reported net income of $303 million, or $1.04 per share, compared with $281 million, or 96 cents per share, in the year-ago ...

Bengaluru: U.S. medical device maker Becton Dickinson is considering a potential separation of its life sciences unit at a valuation of about $30 billion, a person familiar with the matter said on ...

On August 1, Becton, Dickinson will report earnings from the last quarter. Wall Street analysts expect Becton, Dickinson will be reporting earnings per share of $3.31. Go here to track Becton ...

Becton Dickinson BDX1.82%increase; green up pointing triangle agreed to acquire an Edwards Lifesciences EW 1.46%increase; green up pointing triangle unit for $4.2 billion, in one of the company ...

Becton Dickinson & Co (NYSE:BDX) recently announced a dividend of $0.95 per share, payable on 2024-03-29, with the ex-dividend date set for 2024-03-07. As investors look forward to this upcoming ...

Becton Dickinson was the best-performing stock in the S&P 500 after the U.S. Food and Drug Administration (FDA) approved clearance for the medical device maker’s updated infusion system.

Shares of Becton Dickinson hit an all-time high on Monday and were last up 6.1% after the medical device maker received U.S. Food and Drug Administration clearance late on Friday for the market ...